Olverembatinib in treatment of chronic myeloid leukemia with D241E mutation progressed to acute lymphoblastic leukemia: report of 1 case and review of literature
10.3760/cma.j.cn115356-20240810-00125
- VernacularTitle:奥雷巴替尼治疗伴D241E突变慢性粒细胞白血病急淋变1例并文献复习
- Author:
Jianhua NIU
1
;
Xin SHI
;
Wei PANG
;
Xiumei FENG
;
Yongrui WANG
;
Xuemei LI
;
Hua YANG
;
Yanhua PU
Author Information
1. 济南市第四人民医院血液内科，济南 250031
- Keywords:
Leukemia, myelocytic, chronic;
Leukemia, lymphoblastic, acute;
D241E mutation;
BCR-ABL;
Tyrosine kinase inhibitors;
Olverembatinib
- From:
Journal of Leukemia & Lymphoma
2025;34(6):361-365
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacy and safety of olverembatinib in treatment of chronic myeloid leukemia (CML) progressed to acute lymphoblastic leukemia with D241E mutation.Methods:The diagnosis and treatment of a patient with D241E mutant CML progressed to acute lymphoblastic leukemia admitted to the Fourth People's Hospital of Jinan in December 2018 were retrospectively analyzed, and relevant literature was reviewed.Results:The patient was a 47-year-old female, and her blood test result was abnormal during physical examination. She was diagnosed as CML and received treatment with imatinib and dasatinib for 2 years. The disease progressed to philadelphia chromosome (Ph)-positive acute B-lymphoblastic leukemia with BCR-ABL mutation (a D241E mutation). After 3 courses of chemotherapy combined with a targeted drug (ponatinib), the patient achieved complete remission, while the minimal residual disease continued to be positive. The patient received 1 course of chemotherapy combined with olverembatinib from the 4th course of treatment. After olverembatinib monotherapy maintenance therapy for 36 months, the patient achieved molecular complete remission with minimal residual disease. The patient developed complications such as skin pigmentation and elevated lipid levels, but all complications were tolerable.Conclusions:The application of olverembatinib in D241E mutant CML progressed to acute lymphoblastic leukemia can help patients obtain sustained molecular biological remission and good safety.
